AMBICION

AMBICION develops new drugs focused on establishing a global standard treatment for cancer patients. The company's is called product Natural killer T cells or NKT cells, a type of T cells that also have NK cell properties. It is activated by recognizing glycolipid antigens, produce many types of cytokines, and induce both immunostimulation and suppression reactions. NKT cells can induce cell death to cancer cells due to the nature of NK cells, but its direct cytotoxic activity is limited due to the small amount present in the body. NKT cells also have the ability to produce large amounts of cytokines. AMBICION was founded in October 2015 and is headquartered in Tokyo, Japan.